Read our latest white paper about the concepts of quality by design (QbD) & critial quality attributes (CQAs)
Reduce risk of biosimilar development with an orthogonal approach to physicochemical and bioanalytical methods
Read our latest white paper on using orthogonal methods during biosimilar development.
Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more More